Infectious complications of cyclophosphamide treatment for vasculitis

Arthritis & Rheumatism

Volumn 32, Issue 1, 1989, Pages 45-53

  Bradley, John D ^a   Brandt, Kenneth D ^a   Katz, Barry P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; CLINICAL ARTICLE; FEMALE; HUMAN; INFECTION; INFECTION RISK; LEUKOPENIA; MALE; ORAL DRUG ADMINISTRATION; PNEUMONIA; POLYARTERITIS NODOSA; PRIORITY JOURNAL; VASCULITIS; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMAN; MALE; MIDDLE AGE; POLYARTERITIS NODOSA; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VASCULITIS; VIRUS DISEASES; WEGENER'S GRANULOMATOSIS;

EID: 0024586814     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/anr.1780320108     Document Type: Article

References (46)

1. The spectrum of vasculitis: clinical, pathologic, immunologic, and therapeutic considerations
2. Wegener's granulomatosis: studies in eighteen patients and a review of the literature
3. Wegener's granulomatosis
4. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years
5. Cyclophosphamide therapy in Wegener's granulomatosis
6. Wegener's granulomatosis: long‐term followup of patients treated with cyclophosphamide
7. Cyclophosphamide therapy of severe systemic necrotizing vasculitis
8. Neurologic manifestations of systemic vasculitis: a retrospective and prospective study of the clinicopathologic features and responses to therapy in 25 patients
9. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa
10. Isolated angiitis of the central nervous system: prospective diagnostic and therapeutic experience
11. Statistical aspects of the analysis of data from retrospective studies
12. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis)
13. Long‐term follow‐up of periarteritis nodosa
14. Clinical features, prognosis, and response to treatment in polyarteritis
15. The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener's granulomatosis
16. Cyclophosphamide and lymphocyte subpopulations in Wegener's granulomatosis
17. Herpes zoster in patients with treated Wegener's granulomatosis: a possible role of cyclophosphamide
18. A controlled trial of cyclophosphamide in rheumatoid arthritis
19. Long‐term cyclophosphamide therapy in rheumatoid arthritis: a progress report, six years' experience (abstract)
20. Long‐term cyclophosphamide therapy in rheumatoid arthritis
21. Length of life and cause of death in rheumatoid arthritis (abstract)
22. Controlled studies of oral immunosuppressive drugs in lupus nephritis: a long‐term follow‐up
23. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs
24. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
25. Fatal systemic measles in a child receiving cyclophosphamide for nephrotic syndrome
26. Cyclophosphamide and fatal varicella
27. Wegener's granulomatosis with delayed pulmonary and colonic involvement
28. Pneumocystis carinii pneumonia in a patient with polyarteritis nodosa treated with prednisone and cyclophosphamide (letter)
29. Wegener's granulomatosis: treatment with cytotoxic agents and adrenocorticoids
30. Treatment of Wegener's granulomatosis with cyclophosphamide: an outcome analysis (abstract)
31. Inter‐relations between adrenocortical functions and infectious illnesses
32. Corticosteroids in infectious diseases
33. Adrenocortical hormones in infection and immunity
34. Adrenal glucosteroids after twenty years: a review of their chemically relevant consequences
35. Corticosteroids and infections
36. Moniliasis of the mucous membranes and lungs as a complication of treatment with antibiotics, corticotrophin and cortisone
37. Varicella and cortisone
38. Alternate‐day prednisone: leukocyte kinetics and susceptibility to infections
39. Alternate‐day prednisone therapy: evaluation of delayed hypersensitivity responses, control of disease and steroid side effects
40. Studies on an intermittent corticosteroid dosage regimen
41. Alternate‐day steroid therapy in lupus nephritis
42. Bacteruria in rheumatoid arthritis
43. Incidence of infection in systemic lupus erythematosus
44. Alternate‐day prednisone therapy and human lymphocyte subpopulations
45. Daily and alternate‐day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study